NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction.	*09/03/2022*	Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults. **CCG Commissioned**	*Y*			*20/04/2022*	*42 days*
TA774 - Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)	*09/03/2022*	NICE was unable to make a recommendation on lenalidomide (Revlimid) for treating relapsed or refractory mantle cell lymphoma. This is because Celgene did not provide an evidence submission. **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*20/04/2022*	*N/A*
TA775 - Dapagliflozin for treating chronic kidney disease	*09/03/2022*	Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults. **CCG Commissioned**	*Y*			*20/04/2022*	*42 days*
TA776 - Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea	*09/03/2022*	Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults. **Not recommended for prescribing on the NHS in Lancashire**	*Y*			*20/04/2022*	*42 days*
TA777 - Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea	*09/03/2022*	Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults. **Not recommended for prescribing on the NHS in Lancashire**	*Y*			*20/04/2022*	*42 days*
TA778 - Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria	*09/03/2022*	Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor. **NHSE Commissioned**	*Y*			*20/04/2022*	*42 days*
TA779 - Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.	*16/03/2022*	Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy. **Cancer Drug Fund**	*Y*		*N/A*	*20/04/2022*	*35 days*
TA780 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (updates and replaces TA581)	*24/03/2022*	Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults. **NHSE Commissioned**	*Y*			*20/04/2022*	*27 days*
TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	*30/03/2022*	Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults. **Cancer Drug Fund**	*Y*			*20/04/2022*	*21 days*
TA782-Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)	*30/03/2022*	NICE was unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission. **Not recommended for prescribing on the NHS in Lancashire**	*N/A*	*N/A*	*N/A*	*20/04/2022*	*N/A*
TA783 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. (updates and replaces TA510)	*13/04/2022*	Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults. **NHSE Commissioned**	*Y*			*18/05/2022*	*35 days*
TA784 -Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. (updates and replaces TA528)	*20/04/2022*	Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults. **NHSE Commissioned**	*Y*			*18/05/2022*	*28 days*
TA785 - Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)	*20/04/2022*	NICE was unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission. **Not recommended for prescribing on the NHS in Lancashire**	*N/A*	*N/A*		*18/05/2022*	*N/A*
TA786 - Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies.	*27/04/2022*	Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies. **NHSE Commissioned**	*Y*			*18/05/2022*	*21 days*
TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable.	*27/04/2022*	Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. **NHSE Commissioned**	*Y*			*18/05/2022*	*21 days*

NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA788 – Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	*11/05/2022*	Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults. **NHSE Commissioned**	*Y*			*15/06/2022*	*35 days*
TA789 - Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations.	*18/05/2022*	Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults. **NHSE Commissioned**	*Y*			*15/06/2022*	*28 days*
TA790 - TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)	*25/05/2022*	NICE was unable to make a recommendation on TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices because Medtronic withdrew its evidence submission. **Not recommended for prescribing on the NHS in Lancashire**	*N/A*	*N/A*		*15/06/2022*	*N/A*
TA791 - Romosozumab for treating severe osteoporosis	*25/5/2022*	Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture. **CCG Commissioned**	*Y*			*15/06/2022*	*21 days*
TA792 - Filgotinib for treating moderately to severely active ulcerative colitis.	*01/06/2022*	Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment. **CCG Commissioned, Blueteq required**	*Y*			*20/07/2022*	*49 days*
TA793 - Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)	*08/06/2022*	NICE was unable to make a recommendation on anifrolumab (Saphnelo) for active autoantibody-positive systemic lupus erythematosus. This is because AstraZeneca did not provide an evidence submission. **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*20/07/2022*	*N/A*
TA794 - Diroximel fumarate for treating relapsing–remitting multiple sclerosis.	*08/06/2022*	Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults. **NHSE Commissioned**	*Y*			*20/07/2022*	*42 days*
TA795 - Ibrutinib for treating Waldenstrom's macroglobulinaemia (updates and replaces TA491)	*08/06/2022*	Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom's macroglobulinaemia in adults who have had at least 1 previous therapy. **Not recommended for prescribing on the NHS in Lancashire**	*Y*			*20/07/2022*	*42 days*
TA796 - Venetoclax for treating chronic lymphocytic leukaemia (updates and replaces TA487)	*15/06/2022*	Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults. **NHSE Commissioned**	*Y*			*20/07/2022*	*35 days*
TA797 - Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)	*15/06/2022*	NICE was unable to make a recommendation on enfortumab vedotin (Padcev) for previously treated locally advanced or metastatic urothelial cancer. This is because Astellas did not provide an evidence submission. **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*20/07/2022*	*N/A*
TA798 - Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	*22/06/2022*	Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults. **NHSE Commissioned**	*Y*			*20/07/2022*	*28 days*
TA799 - Faricimab for treating diabetic macular oedema	*29/06/2022*	Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults. **ICB Commissioned, Blueteq required**	*Y*			*20/07/2022*	*21 days*
TA800 - Faricimab for treating wet age-related macular degeneration	*29/06/2022*	Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults. **ICB Commissioned, Blueteq required**	*Y*			*20/07/2022*	*21 days*
TA801 - Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer	*29/06/2022*	Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. **NHSE Commissioned**	*Y*			*20/07/2022*	*21 days*
TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma	*29/06/2022*	Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults. **NHSE Commissioned**	*Y*			*20/07/2022*	*21 days*

NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA804 – Teduglutide for treating short bowel syndrome (updates and replaces TA690)	*30/06/2022*	*Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.* ***NHSE Commissioned***	*Y*			*20/07/2022*	*20 days*
TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	*13/07/2022*	*Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*21/09/2022*	*70 days*
TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	*13/07/2022*	*Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.* ***ICB Commissioned***	*Y*			*21/09/2022*	*70 days*
TA806 - Belimumab for treating lupus nephritis (terminated appraisal)	*13/07/2022*	*NICE was unable to make a recommendation on belimumab (Benlysta) for treating lupus nephritis. This is because GlaxoSmithKline did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*	*N/A*		*21/09/2022*	*N/A*
TA807 - Roxadustat for treating symptomatic anaemia in chronic kidney disease	*13/07/2022*	*Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*21/09/2022*	*70 days*
TA808 - Fenfluramine for treating seizures associated with Dravet syndrome	*08/07/2022*	*Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*75 days*
TA809 - Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	*20/07/2022*	*Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*63 days*
TA810 - Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	*20/07/2022*	*Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*63 days*
TA811 - Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)	*27/07/2022*	*NICE was unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments because Secura Bio withdrew its evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*21/09/2022*	*N/A*
TA812 - Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer	*03/08/2022*	*Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.* Not recommended for prescribing on the NHS in Lancashire	*Y*			*21/09/2022*	*49 days*
TA813 - Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	*03/08/2022*	*Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*49 days*
TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	*03/08/2022*	*Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.* ***ICB Commissioned, Blueteq required***	*Y*			*21/09/2022*	*49 days*
TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	*10/08/2022*	*Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*21/09/2022*	*42 days*
TA816 - Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	*10/08/2022*	*Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*42 days*
TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence	*10/08/2022*	*Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*42 days*
TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma	*17/08/2022*	*Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*35 days*

NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	*Yes*	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA819 - Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies	*17/08/2022*	*Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*35 days*
TA820 - Brolucizumab for treating diabetic macular oedema	*31/08/2022*	*Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*21/09/2022*	*21 days*
TA821 - Avalglucosidase alfa for treating Pompe disease	*24/08/2022*	*Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.* ***NHSE Commissioned***	*Y*			*21/09/2022*	*28 days*
TA822 - Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)	*14/09/2022*	*NICE was unable to make a recommendation on melphalan (Phelinun) for treating haematological diseases before allogeneic haematopoietic stem cell transplant because ADIENNE did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*19/10/2022*	*N/A*
TA823 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer	*28/09/2022*	*Evidence-based recommendations on atezolizumab (Tecentriq) for adjuvant treatment of resected non-small-cell lung cancer in adults.* ***NHSE Cancer Drug Fund***	*Y*			*19/10/2022*	*21 days*
TA824 - Dexamethasone intravitreal implant for treating diabetic macular oedema	*14/09/2022*	*Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*19/10/2022*	*35 days*
TA825 - Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis	*21/09/2022*	*Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults* ***NHSE Commissioned***	*y*			*19/10/2022*	*28 days*
TA826 -Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)	*21/09/2022*	*NICE was unable to make a recommendation on vedolizumab (Entyvio) for treating chronic refractory pouchitis after surgery for ulcerative colitis in adults. This is because Takeda did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*19/10/2022*	*N/A*
TA829 - Upadacitinib for treating active ankylosing spondylitis	*30/09/2022*	*Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*19/10/2022*	*48 days*
TA827 - Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	*05/10/2022*	*Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.* ***NHSE Commissioned***	*Y*			*16/11/2022*	*42 days*
TA828 - Ozanimod for treating moderately to severely active ulcerative colitis	*05/10/2022*	*Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.* ***ICB Commissioned, Blueteq required***	*Y*			*16/11/2022*	*42 days*
TA830 - Pembrolizumab for adjuvant treatment of renal cell carcinoma	*19/10/2022*	*Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.* ***NHSE Commissioned***	*Y*			*16/11/2022*	*35 days*
TA831 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	*05/10/2022*	Not recommended for prescribing on the NHS in Lancashire	*Y*			*16/11/2022*	*42 days*
TA832 - Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids	*19/10/2022*	*Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.* ***ICB Commissioned, Blueteq required***	*Y*			*16/11/2022*	*28 days*
TA833 - Zanubrutinib for treating Waldenstrom's macroglobulinaemia	*19/10/2022*	*Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom's macroglobulinaemia in adults.* ***NHSE Commissioned***	*Y*			*16/11/2022*	*28 days*

NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA834 - SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)	*12/10/2022*	*NICE was unable to make a recommendation on SQ HDM SLIT (Acarizax) for treating allergic rhinitis and allergic asthma in adults caused by house dust mites. This is because ALK-Abello did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*16/11/2022*	*N/A*
TA835 - Fostamatinib for treating refractory chronic immune thrombocytopenia (updates and replaces TA759)	*19/10/2022*	*Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*16/11/2022*	*28 days*
TA836 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	*26/10/2022*	*Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.* ***NHSE Commissioned***	*Y*			*16/11/2022*	*21 days*
TA837 - Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma	*26/10/2022*	*Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.* ***NHSE Commissioned***	*Y*			*16/11/2022*	*21 days*
TA838 - Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)	*02/11/2022*	*NICE was unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne withdrew its evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA839 - Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)	*16/11/2022*	*NICE was unable to make a recommendation about the use in the NHS of ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA840 - Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)	*16/11/2022*	*NICE was unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA841 -Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	*22/11/2022*	*NICE was unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA842 - Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)	*22/11/2022*	*NICE was unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory follicular lymphoma in adults after 2 or more therapies. This is because Novartis did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA843 - Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)	*24/11/2022*	*NICE was unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by beta-thalassaemia because BMS did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA844 - Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)	*24/11/2022*	*NICE was unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by myelodysplastic syndromes because BMS did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*
TA845 - Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)	*29/11/2022*	*NICE was unable to make a recommendation on mepolizumab (Nucala) for treating eosinophilic granulomatosis with polyangiitis in people 6 years and over because GSK did not provide an evidence submission.* Not recommended for prescribing on the NHS in Lancashire	*N/A*			*14/12/2022*	*N/A*

NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	*Yes*	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA846 - Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)	*29/11/2022*	*NICE was unable to make a recommendation on mepolizumab (Nucala) for treating severe hypereosinophilic syndrome in adults because GSK did not provide an evidence submission.* **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*14/12/2022*	*N/A*
TA847 - Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)	*29/11/2022*	*NICE was unable to make a recommendation on mepolizumab (Nucala) for treating severe chronic rhinosinusitis with nasal polyps in adults because GSK did not provide an evidence submission.* **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*14/12/2022*	*N/A*
TA848 - Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)	*01/12/2022*	*NICE was unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission.* **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*18/01/2023*	*N/A*
TA849 - Cabozantinib for previously treated advanced hepatocellular carcinoma (updates and replaces TA582)	*14/12/2022*	*Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.* ***NHSE Commissioned***	*Y*			*18/01/2023*	*35 days*
TA850 - Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	*14//12/2022*	*Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.* **Not recommended for prescribing on the NHS in Lancashire**	*Y*			*18/01/2023*	*35 days*
TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	*14/12/2022*	*Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.* ***NHSE Commissioned***	*Y*			*18/01/2023*	*35 days*
TA852 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments	*14/12/2022*	*Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.* ***NHSE Commissioned***	*Y*			*18/01/2023*	*34 days*
TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia	*15/12/2022*	*Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*18/01/2023*	*35 days*
TA854 - Esketamine nasal spray for treatment-resistant depression	*14/12/2022*	*Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.* **Not recommended for prescribing on the NHS in Lancashire**	*Y*			*18/01/2023*	*35 days*
TA855 - Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	*04/01/2023*	*Evidence-based recommendations on mobocertinib (EXKIVITY) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.* ***NHSE Commissioned***	*Y*			*22/02/2023*	*49 days*
TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis	*04/01/2023*	*Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.* ***ICB Commissioned, Blueteq required***	*Y*			*22/02/2023*	*49 days*
TA857 - Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	*11/01/2023*	*Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.* ***NHSE Commissioned***	*Y*			*22/02/2023*	*42 days*
TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma	*11/01/2023*	*Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.* ***NHSE Commissioned***	*Y*			*22/02/2023*	*42 days*
TA859 - Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	*16/01/2023*	*NICE was unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. This is because Paion AG did not provide an evidence submission.* **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*22/02/2023*	*N/A*
TA860 - Maribavir for treating refractory cytomegalovirus infection after transplant	*18/01/2023*	*Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.* ***NHSE Commissioned***	*Y*			*22/02/2023*	*35 days*

NICE Technology Appraisals (medicines): ELHE Formulary Adherence 2022/2023

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA861 - Upadacitinib for treating active non-radiographic axial spondyloarthritis	*01/02/2023*	*Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.* **ICB Commissioned, Blueteq required**	*Y*			*15/03/2023*	*42 days*
TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	*01/02/2023*	*Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.* **NHSE Cancer Drug Fund**	*Y*			*15/03/2023*	*42 days*
TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over	*01/02/2023*	*Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.* **ICB Commissioned, Blueteq required**	*Y*			*15/03/2023*	*42 days*
TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	*01/02/2023*	*Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.* **NHSE Commissioned**	*Y*			*15/03/2023*	*42 days*
TA865 - Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	*08/02/2023*	*Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.* **NHSE Commissioned**	*Y*			*15/03/2023*	*35 days*
TA866 - Regorafenib for previously treated metastatic colorectal cancer	*08/02/2023*	*Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.* **NHSE Commissioned**	*Y*			*15/03/2023*	*35 days*
TA867 - Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)	*16/02/2023*	*NICE was unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission.* **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*15/03/2023*	*N/A*
TA868 - Vutrisiran for treating hereditary transthyretin-related amyloidosis	*15/02/2023*	*Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.* **NHSE Commissioned**	*Y*			*15/03/2023*	*28 days*
TA869 - Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)	*16/02/2023*	*NICE was unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission.* **Not recommended for prescribing on the NHS in Lancashire**	*N/A*			*15/03/2023*	*N/A*
TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (updates and replaces TA505)	*22/02/2023*	*Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.* **NHSE Commissioned**	*Y*			*15/03/2023*	*21 days*
TA872 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (updates and replaces TA559)	*28/02/2023*	*Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.* **NHSE Commissioned**	*Y*			*15/03/2023*	*14 days*
% Total formulary adherence to NICE 2022 2023			***100%***	***0%***	***Average number of days to implement guidance***		***41 days***